BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:Europe/Helsinki X-WR-TIMEZONE:Europe/Helsinki BEGIN:VEVENT UID:358@inflames.utu.fi DTSTART;TZID=Europe/Helsinki:20241003T120000 DTEND;TZID=Europe/Helsinki:20241003T130000 DTSTAMP:20240916T131807Z URL:https://inflames.utu.fi/events/frontiers-of-science-carlos-l-arteaga/ SUMMARY:Frontiers of Science: Carlos L. Arteaga DESCRIPTION:October 3rd at 12:00\nOnsite event\nin Presidentti auditorium\, BioCity\nAutumn 2024 program\n\nProf. Carlos L. Arteaga\, UTSW Harold C. Simmons Comprehensive Cancer Center\, USA\nAre we curing estrogen receptor positive (ER+) breast cancer?\nHost: Klaus Elenius (klaele@utu.fi)\n\nCof fee and sandwich at 11:45\, first come first served!\n\n \;\n\nSix PhD researchers and early-career postdocs are welcome to have a lunch and dis cuss with Prof. Arteaga after the seminar. This is a great possibility to learn hosting skills in a friendly environment and create connections for future. Everyone is welcome to join\, BioCity Turku will offer the lunch.\ n\nIf you got interested\, please send an email to biocityturku@bioscience .fi\n\n \;\n\nThe Arteaga Laboratory has a longstanding interest in un derstanding the molecular pathways that drive breast cancer progression an d influence response to therapies. Their focus is on translational breast cancer research\, aimed at developing therapeutic strategies and identifyi ng biomarkers of drug sensitivity and resistance. The Arteaga Laboratory i ncorporates molecular profiling (next-gen DNA/RNA sequencing) of primary t umors\, biopsies of metastases\, and plasma tumor DNA\, high-throughput CR ISPR and gain-of-function ORF screens\, and mechanistic studies using brea st cancer cell lines\, cell line-derived xenografts\, and patient-derived organoids and xenografts\, to use insights from the laboratory to guide cl inical trials. Dr. Arteaga is an internationally recognized expert in brea st cancer with more than 350 publications in the areas of oncogenes and br east tumor initiation and progression\, targeted therapies and biomarkers of drug action and resistance\, and investigator-initiated clinical trials in breast cancer.\n\n \;\n\nSelected publications\n\nLin CC\, Chang T C\, Wang Y\, Guo L\, Gao Y\, … \, Akamatsu H\, Napolitano F\, Mani R\, C escon DW\, Xu L\, Xie Y\, Mendell JT\, Hanker AB\, Arteaga CL. 2024. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB- deficient breast cancer. Nat Commun. 15(1):2287. doi: 10.1038/s41467-024-4 6495-2.\n\nMarín A\, Mamun AA\, Patel H\, Akamatsu H\, Ye D\, Sudhan DR\, Eli L\, Marcelain K\, Brown BP\, Meiler J\, Arteaga CL\, Hanker AB. 2023. Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer. Cancer Res. 83(18) :3145-3158. doi: 10.1158/0008-5472.CAN-22-3617\n\nLee KM\, Lin CC\, Servet to A\, Bae J\, Kandagatla V\, Ye D\, Kim G\, Sudhan DR\, Mendiratta S\, Go nzález Ericsson PI\, Balko JM\, Lee J\, Barnes S\, Malladi VS\, Tabrizi S \, Reddy SM\, Yum S\, Chang CW\, Hutchinson KE\, Yost SE\, Yuan Y\, Chen Z J\, Fu YX\, Hanker AB\, Arteaga CL. 2022. Epigenetic Repression of STING b y MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibito rs in Triple-Negative Breast Cancer. Cancer Immunol Res. 10(7):829-843. do i: 10.1158/2326-6066.CIR-21-0826.\n\nHanker AB\, Sudhan DR\, Arteaga CL. 2 020. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell 37(4):4 96-513. doi: 10.1016/j.ccell.2020.03.009.\n\n \;\n\nGeneral informatio n\n\n You can download and save all the autumn 2024 FoS-seminars to your calendar from here: https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/\n Regi stration is not needed\, participation list is circulated in the audience\ n If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars\, print out the seminar diary and af ter the seminar ask the BioCity coordinator to sign it https://seafile.utu .fi/d/44a70f80ac1e46a9ad0a/\n Please note that any audio or video recordi ng of the seminars is strictly forbidden.\n Autumn 2024 image credits to Mia Åstrand: Details of the Bacteroides fragilis VgrG protein (PDB ID: 8G RA). Image created in the PyMOL Molecular Graphics System\, Version 2.5 Sc hrödinger\, LLC.\n\n \;\n\n \; ATTACH;FMTTYPE=image/jpeg:https://inflames.utu.fi/wp-content/uploads/artea ga-400.jpg CATEGORIES:Events in English,Tapahtumat END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:DAYLIGHT DTSTART:20240331T040000 TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR